Skip to content
Screener

Reported August 13, 2026 · Before market open

Revenue$18.7MBeat by $6.0M
EPS-$0.33Beat by $0.26
Revenue estimate$12.7M
EPS estimate-$0.59

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$4.8M
EPS estimate-$0.82

FAQ

When did Xilio Therapeutics, Inc. report Q2 2026 earnings?
Xilio Therapeutics, Inc. (XLO) reported Q2 2026 earnings on August 13, 2026 before market open.
What were Xilio Therapeutics, Inc.'s Q2 2026 revenue and EPS?
Xilio Therapeutics, Inc. reported revenue of $18.7M and eps of $-0.33 for Q2 2026.
Did Xilio Therapeutics, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $12.7M by $6.0M. EPS beat the consensus estimate of $-0.59 by $0.26.
How did Xilio Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 131.2% from $8.1M a year earlier and eps declined 106.3% from $-0.16.
Where can I find Xilio Therapeutics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-345753) and the 10-Q periodic report (0001193125-26-345759) directly on SEC EDGAR. The filing index links above go to sec.gov.